Projects / Programmes
Atherosclerosis and thrombosis
January 1, 2019
- December 31, 2024
Code |
Science |
Field |
Subfield |
3.06.00 |
Medical sciences |
Cardiovascular system |
|
1.05.00 |
Natural sciences and mathematics |
Biochemistry and molecular biology |
|
Code |
Science |
Field |
B530 |
Biomedical sciences |
Cardiovascular system |
Code |
Science |
Field |
3.02 |
Medical and Health Sciences |
Clinical medicine |
1.06 |
Natural Sciences |
Biological sciences |
atherosclerosis, thrombosis, etiopathogenesis, preclinical atherosclerosis, endothelial dysfunction, coagulation, systemic infiammatory markers, genetic polymorphisms, drug actions
Data for the last 5 years (citations for the last 10 years) on
March 27, 2024;
A3 for period
2018-2022
Database |
Linked records |
Citations |
Pure citations |
Average pure citations |
WoS |
740 |
42,525 |
41,284 |
55.79 |
Scopus |
702 |
67,395 |
66,089 |
94.14 |
Researchers (41)
Organisations (1)
Abstract
Atherosclerosis and venous thromboembolism are among the most common diseases of the cardiovascular system and among the most common causes of morbidity and mortality in the developed world as well as in developing countries. The etiopathogenesis of both diseases has not yet been fully elucidated, and the new findings from various studies are opening up new questions, while the old dogmas of these diseases are sometimes called into question. Consequently, we want to study the significance of various factors in the pathogenesis of atherosclerosis and venous thrombosis.
The influence of polymorphisms of candidate genes and classical risk factors on the occurrence of peripheral arterial disease and its complications will be studied, and we will additionally test these patients functionally. We will also try to determine the effect of anticoagulation treatment on the outcome of endovascular treatment in patients with peripheral arterial disease. In patients with diabetes, we will examine the degree of amputations in Slovenia. We will continue to determine the effects of various drugs on the aging of the arterial wall and preclinical forms of atherosclerosis. In this context, we will further examine the mechanisms of low-dose statins and sartans in the arterial wall and their effect on the expression of certain genes. We will study the possibilities of preventive modalities on the arterial wall in the elderly, as well as the possibilities for improving the diastolic left ventricular dysfunction. In the field of preventive cardiology, we will investigate the prevalence of cardiovascular diseases at the national level, and in addition try to introduce appropriate registers in the field of cardiovascular rehabilitation and prevention of cardiovascular diseases. We will also study the influence of certain direct oral anticoagulants on various parameters of haemostasis and try to determine their plasma concentrations, with an emphasis on the effects of antidotes. Additionally, the impact of anticoagulant drugs on the incidence of intracranial haemorrhage will be studied. The use of anticoagulation drugs will be further studied in patients following the treatment of acute arterial occlusions.
We expect that with the results of the described and other, additional studies, we will significantly contribute to a better understanding of the pathogenesis of both atherosclerosis and thrombosis, and in addition, in particular, contribute to more effective and safe treatment of patients with the described diseases. The detection of mechanisms of action and efficacy of sustained medications in both conditions will help to more individually address the treatment of both atherosclerotic and venous thrombemolic conditions.
Significance for science
With the proposed research program, we will continue to try to explain the mechanisms of pathogenesis and treatment in the most common cardiovascular diseases, that is, atherosclerosis and thrombosis. These disease entities still represent an important challenge in the research as well as the therapeutic field. The follow-up events will significantly contribute to better patient treatment. With the foreseen research and study of the mechanisms of both the functioning and efficacy of medicines as well as the diseases themselves, i.e. atherosclerosis and venous thrombosis, we will contribute to a better understanding of both diseases and also to important changes and shift of milestones in therapeutic action.
Significance for the country
With the foreseen research, we will try to answer some of the fundamental questions regarding the onset of cardiovascular disease and assess the possibilities of the most effective therapeutic approaches. These diseases fall into the very top of morbidity and mortality in the world as well as in Slovenia. The findings will significantly contribute to the rationalization of the treatment of cardiovascular patients. As before, the findings and acquired knowledge will be transferred both to the Slovenian and international proctor, which means an important promotion of the Republic of Slovenia and its implementation on the map of top-notch knowledge and research areas. Based on the results achieved so far, we have been recognized internationally. The members of the group published the results of their work in top international journals with a high impact factor, presented their work at important international professional congresses and were invited to the leading structures of the most important European associations. The leader of the research group and its members were also entrusted with organizing several important international meetings and congresses. The members of the research group as invited lecturers at European and world congresses presented and will present the results of their research work and thus promote science.
Most important scientific results
Interim report
Most important socioeconomically and culturally relevant results
Interim report